"The US Food and Drug Administration (FDA) has approved lenvatinib (Lenvima, Eisai), in combination with everolimus, for the treatment of patients with advanced renal cell carcinoma who were previously treated with an anti-angiogenic ther"...
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
The safety of INLYTA has been evaluated in 715 patients in monotherapy studies, which included 537 patients with advanced RCC. The data described [see ADVERSE REACTIONS] reflect exposure to INLYTA in 359 patients with advanced RCC who participated in a randomized clinical study versus sorafenib [see Clinical Studies].
The following risks, including appropriate action to be taken, are discussed in greater detail in other sections of the label [see WARNINGS AND PRECAUTIONS]: hypertension, arterial thromboembolic events, venous thromboembolic events, hemorrhage, cardiac failure, gastrointestinal perforation and fistula formation, thyroid dysfunction, wound healing complications, RPLS, proteinuria, elevation of liver enzymes, hepatic impairment and fetal development.
Clinical Trials Experience
The median duration of treatment was 6.4 months (range 0.03 to 22.0) for patients who received INLYTA and 5.0 months (range 0.03 to 20.1) for patients who received sorafenib. Dose modifications or temporary delay of treatment due to an adverse reaction occurred in 199/359 patients (55%) receiving INLYTA and 220/355 patients (62%) receiving sorafenib. Permanent discontinuation due to an adverse reaction occurred in 34/359 patients (9%) receiving INLYTA and 46/355 patients (13%) receiving sorafenib.
The most common ( ≥ 20%) adverse reactions observed following treatment with INLYTA were diarrhea, hypertension, fatigue, decreased appetite, nausea, dysphonia, palmar-plantar erythrodysesthesia (hand-foot) syndrome, weight decreased, vomiting, asthenia, and constipation. Table 1 presents adverse reactions reported in ≥ 10% patients who received INLYTA or sorafenib.
Table 1: Adverse Reactions Occurring in ≥ 10% of
Patients Who Received INLYTA or Sorafenib
|All Gradesb %||Grade 3/4 %||All Gradesb %||Grade 3/4 %|
|Palmar-plantar erythrodysesthesia syndrome||27||5||51||16|
|Pain in extremity||13||1||14||1|
|aPercentages are treatment-emergent,
bNational Cancer Institute Common Terminology Criteria for Adverse Events, Version 3.0
Selected adverse reactions (all grades) that were reported in < 10% of patients treated with INLYTA included dizziness (9%), upper abdominal pain (8%), myalgia (7%), dehydration (6%), epistaxis (6%), anemia (4%), hemorrhoids (4%), hematuria (3%), tinnitus (3%), lipase increased (3%), glossodynia (3%), pulmonary embolism (2%), rectal hemorrhage (2%), hemoptysis (2%), deep vein thrombosis (1%), retinal-vein occlusion/thrombosis (1%), polycythemia (1%), and transient ischemic attack (1%).
Table 2 presents the most common laboratory abnormalities reported in ≥ 10% patients who received INLYTA or sorafenib.
Table 2: Laboratory
Abnormalities Occurring in ≥ 10% of Patients Who Received INLYTA or
|All Gradesa%||Grade 3/4 %||All Gradesa %||Grade 3/4 %|
|Hemoglobin decreased||320||35||< 1||316||52||4|
|Lymphocytes (absolute) decreased||317||33||3||309||36||4|
|Platelets decreased||312||15||< 1||310||14||0|
|White blood cells decreased||320||11||0||315||16||< 1|
|Creatinine increased||336||55||0||318||41||< 1|
|Bicarbonate decreased||314||44||< 1||291||43||0|
|ALT increased||331||22||< 1||313||22||2|
|AST increased||331||20||< 1||311||25||1|
|Hypoglycemia||336||11||< 1||319||8||< 1|
|aNational Cancer Institute Common Terminology Criteria for
Adverse Events, Version 3.0
ALP: alkaline phosphatase; ALT: alanine aminotransferase; AST: aspartate aminotransferase
Selected laboratory abnormalities (all grades) that were reported in < 10% of patients treated with INLYTA included hemoglobin increased (above the upper limit of normal) (9% for INLYTA versus 1% for sorafenib) and hypercalcemia (6% for INLYTA versus 2% for sorafenib).
Read the Inlyta (axitinib) Side Effects Center for a complete guide to possible side effects
In vitro data indicate that axitinib is metabolized primarily by CYP3A4/5 and, to a lesser extent, CYP1A2, CYP2C19, and uridine diphosphate-glucuronosyltransferase (UGT) 1A1.
Co-administration of ketoconazole, a strong inhibitor of CYP3A4/5, increased the plasma exposure of axitinib in healthy volunteers. Co-administration of INLYTA with strong CYP3A4/5 inhibitors should be avoided. Grapefruit or grapefruit juice may also increase axitinib plasma concentrations and should be avoided. Selection of concomitant medication with no or minimal CYP3A4/5 inhibition potential is recommended. If a strong CYP3A4/5 inhibitor must be co-administered, the INLYTA dose should be reduced [see DOSAGE AND ADMINISTRATION and CLINICAL PHARMACOLOGY].
Co-administration of rifampin, a strong inducer of CYP3A4/5, reduced the plasma exposure of axitinib in healthy volunteers. Co-administration of INLYTA with strong CYP3A4/5 inducers (e.g., rifampin, dexamethasone, phenytoin, carbamazepine, rifabutin, rifapentin, phenobarbital, and St. John's wort) should be avoided. Selection of concomitant medication with no or minimal CYP3A4/5 induction potential is recommended [see DOSAGE AND ADMINISTRATION and CLINICAL PHARMACOLOGY]. Moderate CYP3A4/5 inducers (e.g., bosentan, efavirenz, etravirine, modafinil, and nafcillin) may also reduce the plasma exposure of axitinib and should be avoided if possible.
Read the Inlyta Drug Interactions Center for a complete guide to possible interactions
Last reviewed on RxList: 8/15/2014
Additional Inlyta Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.